Acquired Factor VIII deficiency: Rapid and complete remission after immunosuppressive therapy with high dose cyclophosphamide and Rituximab.

被引：0
|
作者：
Tamponi, G [1 ]
Schinco, P [1 ]
Borchiellini, A [1 ]
Valpreda, A [1 ]
Pollio, B [1 ]
Boccadoro, M [1 ]
机构：
[1] Univ Turin, I-10124 Turin, Italy
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3882
引用
收藏
页码：101B / 101B
页数：1
相关论文
共 50 条
  • [31] Progressive intermediate grade Non-Hodgkin's Lymphoma after high dose therapy and autologous peripheral stem cell transplantation (PSCT) has a high response rate to rituximab.
    Tsai, DE
    Moore, HCF
    Porter, DL
    Vaughn, DJ
    Luger, S
    Loh, EL
    Schuster, SJ
    Stadtmauer, EA
    BLOOD, 1998, 92 (10) : 415A - 415A
  • [32] Rituximab, fludarabin and cyclophosphamide followed by high dose therapy with autologous stem cell rescue leads to high molecular remission rate in chronic lymphocytic leukemia patients but relapses are observed.
    Trneny, M
    Salkova, J
    Karban, J
    Cerny, J
    Michalova, K
    Stritesky, J
    Schwarz, J
    Pytlik, R
    Slavickova, A
    BLOOD, 2004, 104 (11) : 948A - 949A
  • [33] High-dose therapy with autologous stem cell transplantation following rituximab, fludarabin and cyclophosphamide leads to excellent response rate and high probability of molecular remission in chronic lymphocytic leukemia patients
    Trneny, M
    Salkova, J
    Karban, J
    Cerny, J
    Michalova, K
    Slavickova, A
    Stritesky, J
    Pytlik, R
    Straub, J
    Koleskova, E
    BONE MARROW TRANSPLANTATION, 2003, 31 : S162 - S162
  • [34] Rapid and complete reconstitution of autologous haemopoiesis after cord blood infusion in treatment-naive patients with severe aplastic anemia receiving high-dose cyclophosphamide/ATG therapy
    Li, Yanxiang
    Sheng, Zhixin
    Niu, Shaona
    Ge, Lifu
    Ren, Cuiai
    Zou, Yandun
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (01) : 45 - 50
  • [35] RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION
    Papajik, Tomas
    Pikalova, Zuzana
    Raida, Ludek
    Skoumalova, Ivana
    Vondrakova, Jana
    Faber, Edgar
    Prochazka, Vit
    Kubova, Zuzana
    Kucerova, Ladislava
    Pavlik, Tomas
    Dusek, Ladislav
    Indrak, Karel
    BIOMEDICAL PAPERS-OLOMOUC, 2009, 153 (03): : 211 - 214
  • [36] Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity
    Scalvenzi, Massimiliano
    Cappello, Milena
    Costa, Claudia
    Fabbrocini, Gabriella
    Luciano, Mariaantonietta
    Villani, Alessia
    DERMATOLOGY AND THERAPY, 2020, 10 (03) : 465 - 468
  • [37] Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity
    Massimiliano Scalvenzi
    Milena Cappello
    Claudia Costa
    Gabriella Fabbrocini
    Mariaantonietta Luciano
    Alessia Villani
    Dermatology and Therapy, 2020, 10 : 465 - 468
  • [38] Intensive treatment with high-dose melphalan as initial therapy in newly-diagnosed patients with multiple myeloma: key to attain rapid complete remission (CR)
    Powles, R
    Sirohi, B
    Goyal, S
    Treleaven, J
    Sankpal, S
    Lloyd, C
    Rudin, C
    Rao, S
    Kulkarni, S
    BONE MARROW TRANSPLANTATION, 2002, 29 : S97 - S98
  • [39] Achievement of Complete Remission After High-Dose Melphalan and Autologous Stem Cell Transplantation Is the Only Important Prognostic Factor in Patients with Multiple Myeloma
    Shin, Seunghwan
    Kim, Jeong-A
    Lee, Bohee
    Min, Chang Ki
    Kwak, Jae-Yong
    Yhim, Ho-Young
    BLOOD, 2011, 118 (21) : 882 - 883
  • [40] Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses
    Lamanna, Nicole
    Jurcic, Joseph G.
    Noy, Ariela
    Maslak, Peter
    Gencarelli, Alison N.
    Panageas, Katherine S.
    Heaney, Mark L.
    Brentjens, Renier J.
    Golde, David W.
    Scheinberg, David A.
    Zelenetz, Andrew D.
    Weiss, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 491 - 497
12345